Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
SB 431542: ALK5 Inhibitor Protocols for TGF-β Pathway Resear
2026-07-23
SB 431542 is a benchmark ALK5 inhibitor, central to dissecting TGF-β signaling in both cell-based and animal models. This guide translates cutting-edge research and practical troubleshooting into actionable protocols, revealing how to maximize reproducibility and performance in regenerative, cancer, and immunology workflows.
-
NP-40 Lysis Buffer: Reliable Non-Denaturing Extraction (SKU
2026-07-23
This scenario-driven guide explores how NP-40 Lysis Buffer (SKU K1127) addresses reproducibility and protein integrity challenges in cell viability, proliferation, and cytotoxicity assays. Benchmarked against real-world protocols, this evidence-based resource highlights buffer selection, protocol optimization, and data interpretation for animal, plant, fungal, and bacterial samples.
-
AZD3463 ALK/IGF1R Inhibitor: Workflows & Troubleshooting Gui
2026-07-22
AZD3463, a next-generation ALK/IGF1R inhibitor, enables robust PI3K/AKT/mTOR pathway studies and apoptosis induction in neuroblastoma models—including those harboring resistance mutations. This guide translates bench protocols, optimization strategies, and cross-study insights for researchers seeking superior targeting, reproducibility, and translational impact.
-
Vincristine Sulfate: Mechanism, Efficacy, and Protocols
2026-07-22
Vincristine sulfate is a potent microtubule disrupter widely used in cancer research. Its precise mechanism, verified efficacy in leukemia and lymphoma, and well-characterized solubility make it a benchmark antitumor agent.
-
SB 431542: A Potent ALK5 Inhibitor for TGF-β Pathway Researc
2026-07-21
SB 431542 is a highly selective ATP-competitive ALK5 inhibitor leveraged in studies of TGF-β signaling and immunomodulation. It blocks Smad2 phosphorylation, inhibits glioma cell proliferation, and is validated for anti-tumor immunity research. APExBIO provides SB 431542 (SKU A8249) as a research-grade compound.
-
Danazol (SKU C3644): Reliable Steroidogenesis Inhibition in
2026-07-21
This article addresses key laboratory challenges in endocrine and cytotoxicity assays, focusing on the robust use of Danazol (SKU C3644) for reproducible androgen receptor modulation and steroidogenesis inhibition. Drawing on peer-reviewed studies and validated workflows, it demonstrates how APExBIO's Danazol supports data consistency and translational relevance for biomedical researchers.
-
Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im
2026-07-20
This study presents a new patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, more faithfully capturing tumor microenvironment complexity. The model enables deeper investigation of tumor–stroma interactions, gene expression, and drug responses, highlighting its value for personalized cancer research and drug screening.
-
ALDH1A3-miR-7-TGFBR2-Smad3 Axis Controls CD44 in Breast CSCs
2026-07-20
This study uncovers a regulatory pathway in breast cancer stem cells where ALDH1A3 knockdown upregulates miR-7, leading to decreased CD44 expression via the TGFBR2/Smad3 axis. These findings clarify molecular mechanisms governing stemness in breast cancer and offer new targets for limiting tumor recurrence.
-
SB-505124 Hydrochloride: Advanced Insights into TGF-β Pathwa
2026-07-19
Explore the unique mechanistic and methodological value of SB-505124 hydrochloride in dissecting TGF-β signaling and cellular stiffness regulation. This article delivers an advanced, research-driven perspective for fibrosis, cancer, and mechanobiology studies.
-
FGFR-TGFβ-PI3K/AKT Crosstalk Regulates Periostin in HER2+ Br
2026-07-18
Labrèche et al. uncover a complex regulatory network controlling periostin expression in HER2/neu-positive breast cancer cells, governed by FGFR, TGFβ, and PI3K/AKT signaling cross talk. These insights clarify cell-type specific drivers of tumor aggressiveness and suggest new mechanistic targets for therapeutic intervention.
-
Gut Microbiota, AMPK, and Probiotic Intervention in Alcoholi
2026-07-17
This study demonstrates that Lactiplantibacillus plantarum P101 (LP.P101) alleviates alcohol-induced hepatic lipid accumulation in mice by activating AMPK, with gut microbiota and metabolomic changes playing a pivotal role. Using the AMPK inhibitor Dorsomorphin, the work robustly connects probiotic action to the AMPK pathway, providing mechanistic clarity and translational potential for metabolic research.
-
AZD3463: A High-Affinity ALK/IGF1R Inhibitor for Neuroblasto
2026-07-17
AZD3463 is a potent, orally bioavailable ALK/IGF1R inhibitor with nanomolar affinity, enabling robust inhibition of the PI3K/AKT/mTOR pathway and apoptosis in neuroblastoma models. Its selectivity for wild-type and mutant ALK makes it a benchmark tool in ALK-driven cancer research.
-
Dorsomorphin (Compound C) in Immune Metabolism and Macrophag
2026-07-16
Explore how Dorsomorphin (Compound C) advances research on AMPK inhibition, macrophage polarization, and metabolic inflammation. This in-depth analysis reveals unique mechanistic insights and assay guidance for immunometabolic studies.
-
Cholesterol in Lipid Nanoparticles: Elevating mRNA Delivery
2026-07-16
Cholesterol is more than a membrane component—it's the principal sterol central to the design of effective lipid nanoparticles for mRNA-based therapies. Discover experimental protocols, troubleshooting insights, and translational advances leveraging APExBIO’s high-purity cholesterol in cancer-focused research.
-
Everolimus (RAD001) in Cancer Research: Workflow and Trouble
2026-07-15
Everolimus (RAD001) stands out as a robust, orally bioavailable mTOR inhibitor for dissecting cancer cell proliferation and apoptosis. This article translates the latest methodological insights into actionable experimental workflows, protocol enhancements, and troubleshooting strategies, ensuring reproducibility and data clarity in both in vitro and in vivo oncology research.